↓ Skip to main content

Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

Overview of attention for article published in The Journal of Law, Medicine & Ethics, January 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
26 Mendeley